Pharmaceutical companies have intensively ushered in high-level personnel changes, and the positions of general managers/deputy general managers have changed frequently

[Pharmaceutical Network Industry News] In the pharmaceutical industry, pharmaceutical companies are intensively ushering in high-level personnel chang.
Almost every month, there are news of pharmaceutical company executives leaving and new appointmen.
The pharmaceutical company has changed 9 times in the past year, and Renhe Pharmaceutical issued an announcement at noon on July 26, saying that the company's board of directors received the company's director and general manager, .
Zhang Wei, and deputy general manager, .
Wang Zhen, on July 26, 202 Submitted written resignation repo.
.
Zhang Wei resigned due to job adjustment, and .
Wang Zhen resigned due to personal reaso.
On the same day, Renhe Pharmaceutical announced that the company's board of supervisors received a written resignation report submitted by the company's employee representative supervisor, .
Huang Wujun, on July 26, 202.
Huang Wujun resigned due to job adjustme.
Since the beginning of this year, Renhe Pharmaceutical’s personnel change is not the first ti.
The last time the company issued a personnel change announcement was on March 5, 202 At that time, the company issued a number of independent director nominees statements, including Guo Yaxiong, Tu Shutian, Wang Yuesheng,e.
According to statistics, Renhe Pharmaceutical has issued a total of 9 personnel change announcements in the past ye.
According to the reply from the board secretary of Renhe Pharmaceuticals on the investor relations platform in July, Renhe Pharmaceuticals is a production and sales enterprise that mainly produces and sells medicines (81% of over-the-counter OTC products and 19% of prescription drugs) and big health produc.
The company's traditional Chinese medicine varieties account for about 45% of all drug varieti.
The company's drug research and development mainly focuses on large varieties of generic drugs and national traditional Chinese medicine classic prescriptions, such as oseltamivir phosphate capsules, sodium hyaluronate eye drops, e.

, national traditional Chinese medicine The Classic Prescription Company has 16 classical Chinese medicine prescriptions under developme.

The 2021 annual report shows that the company achieved a total operating income of 94 billion, a year-on-year increase of 14%; realized a net profit attributable to the parent of 670 million, a year-on-year increase of 16%; earnings per share was 48 yuan
In addition, according to the 2022 first quarter report, the company's main income was 311 billion yuan, a year-on-year increase of 66%; the net profit attributable to the parent was 156 million yuan, a year-on-year increase of 95%; the deducted non-net profit was 142 million yuan, a year-on-year decrease of 84%; the debt ratio was 14% , the investment income is 8694 million yuan, the financial cost is -6335 million yuan, and the gross profit rate is 34
The position of general manager/deputy general manager changed frequent.

In the second half of the year, senior executives of pharmaceutical companies changed frequently, including Renhe Pharmaceutical, Fosun Pharma, Teyi Pharmaceutical, Pien Tze Huang, Asymchem, Ma Yinglong, and Guangyuyuan since June alo.

Nearly 100 senior executives of more than 30 pharmaceutical companies have changed, including many general managers and deputy general manage.

For example, on June 17, Jichuan Pharmaceutical issued a personnel change announcement saying that Liu Jun, the company's director and deputy general manager, applied for resignation due to personal reaso.

On the same day, Zhenghai Biological announced that the board of directors recently received a written resignation report from the company's deputy general manager, Shi Yanfe.

Shi Yanfeng applied for his resignation as deputy general manager of the company due to personal reaso.

Tai An Tang announced on June 15 that the board of directors of the company recently received a written resignation from Zhuang Qiming, the deputy general manag.

Due to personal reasons, Zhuang Qiming applied for his resignation as the deputy general manager of the compa.

Dawei Medical announced on the evening of June 9 that .

Ma Jianmin, Deputy General Manager of Ningbo Dawei Medical Equipment .

, L.

, applied to resign from the position of Deputy General Manager of the company due to personal reaso.

The company's subsidiary company Ningbo Yongxing Medical Instrument .

, L.

is the executive director and general manag.

Yipinhong announced on the evening of June 7 that .

Xie Xiaohua applied for his resignation as the company's deputy general manager and board secretary due to personal reasons, and would no longer hold any positions in the company after his resignati.
Daan Gene announced on the evening of June 6 that the board of directors of the company received a written resignation report from Zhou Xinyu, the general manager of the company, on June 6, 202 He resigned as the general manager of the company due to personal and physical health reaso.

Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.